I-MAB (IMAB) has released an update.
I-Mab, a biotech company specializing in cancer immunotherapies, has revealed promising Phase 1 clinical data for its PD-L1x4-1BB bispecific antibody, Ragistomig, indicating a manageable safety profile and significant efficacy in patients previously treated with checkpoint inhibitors. With one complete response and multiple partial responses observed in heavily pre-treated patients, the company is set to present these findings at the ASCO 2024 and is optimistic about the potential of Ragistomig as a new treatment option for cancer patients resistant to current therapies.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
